Liraglutide reduced stool frequency in a small subset of patients with bile acid diarrhea and warrants consideration as a potential new treatment modality, according to research in The Lancet Gastroenterology and Hepatology.
Researchers aimed to investigate the safety and efficacy of liraglutide, a glucagon-like peptide 1 receptor agonist, in patients with bile acid diarrhea, which is often